Belgium· BE-AMP-SAM592720-00
Opdivo 10 mg/ml
A nivolumab product containing nivolumab, registered in Belgium by Bristol-Myers Squibb Pharma. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Nivolumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FF01 (nivolumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Nivolumab · ATC L01FF01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Nivolumab
- Manufacturer
- Bristol-Myers Squibb Pharma
- Country
- Belgium (BE)
- ATC code
- L01FF01
- ATC class
- Nivolumab
- Defined daily dose
- 17.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7736325
- be_apb4474664
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for nivolumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nivolumab · interactions on record
22 records
- 3 severe
- 19 moderate
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nivolumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandNivolumab BmsBristol-Myers Squibb Pharma EEIG
- CzechiaOPDIVOBristol-Myers Squibb Pharma EEIG, Dublin
- IcelandOpdivoBristol-Myers Squibb Pharma EEIG*
- NorwayOpdivoBristol-Myers Squibb Pharma EEIG
- PolandOpdivoBristol-Myers Squibb Pharma EEIG
- SwedenOPDIVO 10 mg/ml Koncentrat till infusionsvätska, lösningBristol-Myers Squibb Pharma EEIG
- SwitzerlandOpdivo 120 mg/12 ml, Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
- IrelandOPDIVO 10 mg/mL concentrate for solution for infusionBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Opdivo
- Liechtenstein · Opdivo
- Norway · Opdivo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7fced568-9f13-4f7a-8c56-d394cc0a2e9f GET /v1/drugs/7fced568-9f13-4f7a-8c56-d394cc0a2e9f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Opdivo 10 mg/ml",
"name_fr": "Opdivo 10 mg/ml",
"name_nl": "Opdivo 10 mg/ml",
"amp_code": "SAM592720-00",
"strengths": [
"10.0000",
"2.5000"
],
"pack_count": 2,
"substances": [
"Nivolumab",
"Mannitol",
"Polysorbate 80",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Nivolumab",
"authorisation_numbers": [
"EU/1/15/1014/004"
]
}See everything about nivolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.